Aflibercept, ranibizumab and bevacizumab upcoming biosimilars : a general overview
Copyright 2021 Clarivate Analytics..
Anti-vascular endothelial growth factors currently are the first-line treatment option for neovascular age-related macular degeneration (nAMD) and other retinal vascular disorders, and their clinical use is associated with high financial burden. Biosimilars are a type of biological product highly similar to referral biologic drugs; they are increasing competition among biologics and have the potential to reduce the overall expenditures on biologics. In this comprehensive literature review, the current investigational biosimilars acting on retinal diseases are discussed. The authors review the results of clinical studies and highlight ongoing trials. Several biosimilar candidates are under evaluation and the pipeline will rapidly change in the future, as soon as each patent expires. Clinicians have to know these new therapeutic agents, which might come in the mainstream clinical practice as a more cost-efficient option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 11 vom: 21. Nov., Seite 689-697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Viola, P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.11.2021 Date Revised 29.11.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.11.3331006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333590449 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333590449 | ||
| 003 | DE-627 | ||
| 005 | 20231225221945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.11.3331006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333590449 | ||
| 035 | |a (NLM)34821882 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Viola, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aflibercept, ranibizumab and bevacizumab upcoming biosimilars |b a general overview |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2021 | ||
| 500 | |a Date Revised 29.11.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a Anti-vascular endothelial growth factors currently are the first-line treatment option for neovascular age-related macular degeneration (nAMD) and other retinal vascular disorders, and their clinical use is associated with high financial burden. Biosimilars are a type of biological product highly similar to referral biologic drugs; they are increasing competition among biologics and have the potential to reduce the overall expenditures on biologics. In this comprehensive literature review, the current investigational biosimilars acting on retinal diseases are discussed. The authors review the results of clinical studies and highlight ongoing trials. Several biosimilar candidates are under evaluation and the pipeline will rapidly change in the future, as soon as each patent expires. Clinicians have to know these new therapeutic agents, which might come in the mainstream clinical practice as a more cost-efficient option | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aflibercept | |
| 650 | 4 | |a Anti-vascular endothelial growth factor (VEGF) drugs | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a Biosimilars | |
| 650 | 4 | |a Intravitreal injections | |
| 650 | 4 | |a Macular degeneration | |
| 650 | 4 | |a Ranibizumab | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a aflibercept |2 NLM | |
| 650 | 7 | |a 15C2VL427D |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Ranibizumab |2 NLM | |
| 650 | 7 | |a ZL1R02VT79 |2 NLM | |
| 700 | 1 | |a Testa, V |e verfasserin |4 aut | |
| 700 | 1 | |a Ferro Desideri, L |e verfasserin |4 aut | |
| 700 | 1 | |a Di Cello, L |e verfasserin |4 aut | |
| 700 | 1 | |a Rutigliani, C |e verfasserin |4 aut | |
| 700 | 1 | |a Vagge, A |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolò, M |e verfasserin |4 aut | |
| 700 | 1 | |a Cian, R |e verfasserin |4 aut | |
| 700 | 1 | |a Traverso, C E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 11 vom: 21. Nov., Seite 689-697 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:11 |g day:21 |g month:11 |g pages:689-697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.11.3331006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 11 |b 21 |c 11 |h 689-697 | ||